Light exposure or NB-UVB phototherapy appears to improve the efficacy of JAK inhibitors for vitiligo. Dear Editor, Vitiligo is a chronic autoimmune disease that results from the destruction of melanocytes. 1).[3] The use of an oral JAK inhibitor (tofacitinib) and ruxolitinib, a topical JAK inhibitor recently approved by the FDA for use in mild-to-moderate atopic dermatitis, has been observed to be beneficial in the treatment of vitiligo and in conjunction with light therapy. [Extracted from the article]